Временные рекомендации16 декабря 2020 г.
В настоящем документе кратко представлены текущие рекомендации ВОЗ по ведению эпиднадзора в области
общественного здравоо...хранения за коронавирусной инфекцией 2019 г. (COVID-19) у людей, вызываемой коронавирусом
тяжелого острого респираторного синдрома-2 (SARS-CoV-2).
COVID-19 Sanitary and epidemiological monitoring
more
This article is part four in a series of explainers on vaccine development and distribution
Available in different languages
This document offers tools to help journalists practice responsible coverage of the pandemic using evidence-based information. It also proposes ways to approach coverage and encourages journalists to provide advice and solutions that can help reduce health risks and save lives.
В мае 2016 г. Всемирная ассамблея здравоохранения приняла первую Глобальную стратегию сектора здравоохранения (ГССЗ) по проблеме вирусных гепатитов. В ней б...ыла провозглашена цель к 2030 г. добиться элиминации вирусных гепатитов как угрозы общественному здоровью путем реализации (с достаточным уровнем охвата) пяти следующих основных вмешательств: иммунизация против гепатита B; профилактика передачи вируса гепатита B (ВГВ) от матери ребенку; обеспечение безопасности донорской крови и инъекций; принятие мер снижения вреда для людей, употребляющих инъекционные наркотики; предоставление услуг тестирования и лечения. Механизм ВОЗ по мониторингу и оценке в отношении вирусных гепатитов B и C соответствует подходу, ориентированному на результаты, который учитывает такие факторы, как контекст (распространенность инфекции), вкладываемые ресурсы, промежуточные и итоговые результаты (включая каскад мер профилактики, тестирования и лечения) и исходы (заболеваемость и смертность). Системы данных, необходимые для функционирования этого механизма, включают (i) эпиднадзор за ост-рыми гепатитами, случаями хронической инфекции и последствиями;* (ii) оперативные сведения, документирующие меры профилактики, тести-рования и лечения, которые включают каскад услуг медицинской помощи.
more
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv...e equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
WHO-2019-nCoV-genomic_sequencing
Основные аспекты обеспечения биологической безопасности в лабораторных условиях в связи с распространением вируса SARS-CoV
23 February 2021
This document describes the medical devices required for the clinical management of COVID-19, selected and prioritized according to the latest available evidence and interim guidelines. This includes: oxygen therapy, pulse oximeters, patient monitors, thermometers, infusion and suc...tion pumps, X-ray, ultrasound and CT scanners as well as personal protective equipment. In order to facilitate access to quality assured priority medical devices, the document also includes technical and performance characteristics, related standards, accessories and consumables. It is intended for policy-makers and planning officers in Ministries of Health, procurement and regulatory agencies, intergovernmental and international agencies as well as the medical device industry.
This document is an update to the List of priority medical devices for COVID-19 case management and Technical specifications for invasive and non-invasive ventilators for COVID-19.
This document complements the Technical specifications of personal protective equipment for COVID-19.
more
23 February 2021
This document describes the medical devices required for the clinical management of COVID-19, selected and prioritized according to the latest available evidence and interim guidelines. This includes: oxygen therapy, pulse oximeters, patient monitors, thermometers, infusion and suc...tion pumps, X-ray, ultrasound and CT scanners as well as personal protective equipment. In order to facilitate access to quality assured priority medical devices, the document also includes technical and performance characteristics, related standards, accessories and consumables. It is intended for policy-makers and planning officers in Ministries of Health, procurement and regulatory agencies, intergovernmental and international agencies as well as the medical device industry.
This document is an update to the List of priority medical devices for COVID-19 case management and Technical specifications for invasive and non-invasive ventilators for COVID-19.
This document complements the Technical specifications of personal protective equipment for COVID-19.
more
The document "Priority medical devices list for the COVID-19 response and associated technical specifications" complements this guideline.
This document provides interim guidance on the quality, performance characteristics and related standards of personal protective equipment (PPE) to be used i...n the context of COVID-19. This includes WHO Priority Medical Devices, specifically: surgical masks, non-surgical masks, gloves, googles, face shields, gowns and N95 masks. It is intended for procurement agencies, occupational health departments, infection prevention and control departments or focal points, health facility administrators, biomedical and materials engineering, PPE manufacturers and public health authorities at both national and facility levels.
more
16 December 2020. This document summarizes current WHO guidance for public health surveillance of coronavirus disease 2019 (COVID-19) in humans caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (hereafter referred to as COVID19 surveillance).
based on information as at 28 February 2021
Rapid Policy Brief Series Series 14: COVID-19 and hypertension
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Vaccines are supported by decades of medical research. ...They work by preparing the body's own immune system to recognise and defend against a specific disease. The volume of information available about vaccination can be overwhelming, so it’s important to talk through the topic.
Available in different languages
more